Citations

Showing 10 of 108094 citations.

Virtual and Augmented Reality in Management of Phantom Limb Pain: A Systematic Review
Eldaly, Abdullah S. , Ávila, Francisco R. , Maita, Karla C. , Serrano, Luiza Palmieri , Emam, Omar S. , Forte, Antonio J. , Torres-Guzman, Ricardo A, Forte, Antonio Jorge , Eldaly, Abdullah , Avila, Francisco R , Torres‐Guzman, Ricardo A. , Garcia, John P.

Mayo Clinic

HAND | November 5, 2022 | Volume: 19 | Issue: 4 | Pages: 545-554

10.1177/15589447221130093 | PMID 36341580 Get It

Upper and lower limb amputations are frequently associated with phantom limb pain (PLP). Recently, virtual reality (VR) and augmented reality (AR) have been reported as a potential therapy of PLP. We have conducted a systematic review of literature to evaluate the efficacy of VR and AR in managing PLP. Four databases were searched: PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, and Web of Science. We utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for our organization. The initial search resulted in 164 results. After title, abstract, and full-text screening, 9 studies were included. One study was of good quality and 8 studies were of fair to poor quality. Seven studies utilized VR and 2 studies utilized AR. The number of treatment sessions ranged from 1 to 28 and the duration ranged from 10 minutes to 2 hours. Several pain scales were used to evaluate PLP pre- and postintervention including Numeric Rating Scale, Pain Rating Index, McGill Pain Questionnaire, and Visual Analog Scale. All the studies reported improvement of PLP on one or more of pain scales after one or more sessions of VR or AR. Despite the promising results reported by literature, we cannot recommend using VR or AR for PLP. Most of the studies are of poor design and have limited sample size with high bias levels. Therefore, no substantial evidence can be derived from them. However, we do believe further research with high-quality randomized controlled trials should take place to increase the knowledge of the potential advantages.
A Methodological Approach for Documenting Multi-Component Interventions Targeting Family Caregivers
Griffin, Joan M. , Vanderboom, Catherine E., Gustavson, Allison M. , Ingram, Cory , Wild, Ellen, Dose, Ann Marie , Mandrekar, Jay , Holland, Diane E. , Holland, Diane E , Griffin, Joan M , Kaufman, Brystana G.

Mayo Clinic

Journal of Applied Gerontology | November 5, 2022 | Volume: 42 | Issue: 3 | Pages: 487-492

10.1177/07334648221137882 | PMID 36341961 Get It

Managing the complex care needs of seriously ill patients transitioning from hospital to home can have detrimental effects on family caregivers (FCG). Multi-component interventions tailored to FCG needs are most effective at reducing caregiver burden, distress, and depression. However, gaps exist in determining best methods to assess, document, and analyze intervention components for FCGs. Common methods used to capture patient data during transitions in care may not be appropriate or allowed for FCG needs. As such, we present a methodological approach for electronically capturing, reporting, and analyzing multiple intervention components. This approach uses a standardized terminology and pathway for tailoring intervention components in real time while evaluating intervention effects across time. We use examples from a randomized controlled trial to illustrate the benefits of the current approach for analyzing the effectiveness of multi-component interventions in the context of caregiving research.
Mid‐Term Outcomes of the All‐Soft Quadriceps Tendon Autograft Are Noninferior to Hamstring Autograft in Primary Anterior Cruciate Ligament Reconstruction: Comparison With Minimum 5‐Year Follow‐Up
Brinkman, Joseph C. , Tummala, Sailesh V. , Hassebrock, Jeffrey D. , McQuivey, Kade S. , Makovicka, Justin L. , Economopoulos, Kostas J. , Hassebrock, Jeffrey D , Tummala, Sailesh V , Economopoulos, Kostas J

Mayo Clinic

Arthroscopy | November 4, 2022 | Volume: 39 | Issue: 4 | Pages: 1008-1013

10.1016/j.arthro.2022.10.035 | PMID 36343766 Get It

Purpose To compare the 5‐year clinical and functional outcomes of the soft‐tissue quadriceps tendon (QT) with those of the hamstring tendon (HT) autograft. Methods A retrospective review of patients undergoing anterior cruciate ligament reconstruction using either soft‐tissue QT or double‐tendon HT autograft with at least 5 years of follow‐up was conducted. Surgical technique included anteromedial portal creation for the femoral tunnel and transtibial technique for the tibia. Graft fixation was achieved with interference composite screws for the QT and combination of interference composite screw and suture button for the HT cohort. The 2 groups were compared for differences in outcomes, including International Knee Documentation Committee (IKDC) score, Lysholm score, return to sport, and complications. Results A total of 37 patients with QT autograft and 46 HT autografts were included in the study, with a mean follow up of 69.9 months and 70.9 months, respectively. The QT group demonstrated a larger graft size on average (9.64 mm vs 7.90 mm, P < .001). The IKDC and Lysholm scores were similar between the 2 groups at 2‐years’ postoperatively. At 5 years’ postoperatively, the QT group demonstrated significantly greater IKDC ( P = .018) and Lysholm ( P = .007) scores. The cohorts demonstrated similar rates of achieving minimal clinically important difference thresholds at both 2 and 5 years’ postoperatively. The 2 groups also demonstrated comparable rates of return to sport, time to return, and postoperative complications. Conclusions Although the QT autograft demonstrated increased patient‐reported outcome scores when compared with the HT at 5 years’ postoperatively, there was no clinically significant difference between the cohorts at 2 or 5 years’ postoperatively. The QT autograft is an effective alternative to HT autograft with noninferior results to the HT autograft at mid‐term follow‐up. Level of Evidence III, retrospective comparison study.
Conditional Survival in Multiple Myeloma and Impact of Prognostic Factors Over Time
Abdallah, Nadine , Geyer, Susan, Binder, Moritz , Greipp, Patricia T. , Kapoor, Prashant , Gertz, Morie A. , Baughn, Linda B. , Lacy, Martha Q. , Hayman, Suzanne R. , Hwa, Yi L. , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Gertz, Morie A , Binder, Moritz , Baughn, Linda B , Greipp, Patricia T , Smith, Alexandra , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Lin, Yi , Rajkumar, S. Vincent

Mayo Clinic

No container title available | November 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2206884/v1 Get It

Abstract Overall Survival estimates from diagnosis are valuable for guiding treatment, but do not consider the years already survived. Conditional survival (CS) provides dynamic survival predictions over time. This study was conducted to estimate CS at 1–8 years from diagnosis and the impact of baseline prognostic factors on CS in multiple myeloma (MM) patients. This is a retrospective study including 2556 MM patients diagnosed between 2004–2019. CS (t|s) was defined as the probability of surviving t years given survival of s years. Median age was 64 years. Median follow-up was 6.2 years and median overall survival from diagnosis was 7.5 years. The 5-year CS estimates at s = 0, 1, 2, 3, and 5 years were 0.64, 0.61, 0.61, 0.61, and 0.58, respectively. On multivariate analysis, age ≥ 65 and proteasome inhibitor + immunomodulatory-based induction were associated with decreased survival and increased survival, respectively, retained at 5 years. The adverse impact of 1q gain/amplification, high-risk IgH translocation, and ISS-3 was significant at 1 and 3 years but not 5 years. Chromosome 17 abnormality was associated with decreased survival only at 1 year. Among MM patients, 5-year CS was stable at 1–5 years from diagnosis. The prognostic impact of high-risk cytogenetic factors decreased with additional years survived.
IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer
Mucci, Lorelei A. , Vinson, Jacob, Gold, Theresa Margaret, Gerke, Travis , Filipenko, Julie, Green, Rebecca , Anderson, Simon , Badal, Simone , Bjartell, Anders , N., Kim , Davis, Ian D. , Enting, Deborah , Fay, André P. , Mateo, Joaquı́n , McDermott, Ray , Olmos, David , Omlin, Aurelius , Popoola, Ademola , Ragin, Camille , Roberts, Robin , Russnes, Kjell M. , Waihenya, Charles, Hyslop, Terry , Villanti, Paul , George, Daniel J. , Team, on behalf of the IRONMAN Global, Green, Rebecca M , Anderson, Simon G , Chi, Kim N , Mateo, Joaquin , McDermott, Ray , Odedina, Folakemi , Olmos, David , Omlin, Aurelius , Popoola, Ademola A , Ragin, Camille , Roberts, Robin , Stopsack, Konrad H , George, Daniel J , Lazarus, J. Michael , Stopsack, Konrad H. , Kantoff, Philip W. , Team, on behalf of the IRONMAN Global

Mayo Clinic

JCO Global Oncology | November 4, 2022 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/go.22.00154 | PMID 36332173 Get It

PURPOSE To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. PATIENTS AND METHODS Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires. RESULTS Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service. CONCLUSION To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Ray, Kausik K. , Kallend, David , Raal, Frederick J. , Jaros, Mark, Schwartz, Gregory G. , Landmesser, Ulf , Conde, Lorena Garcia , Wright, R. Scott , Investigators, ORION-11, Raal, Frederick J , Landmesser, Ulf , Wright, R Scott , Ray, Kausik K , Leiter, Lawrence A. , Köenig, Wolfgang , Investigators, ORION-11

Mayo Clinic

European Heart Journal | November 4, 2022 | Volume: 43 | Issue: 48 | Pages: 5047-5057

10.1093/eurheartj/ehac615 | PMID 36331315 Get It

Abstract Aims Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisin/kexin type 9 production, in primary prevention patients with elevated LDL-C despite statins. Methods and results This pre-specified analysis of the placebo-controlled, randomized ORION-11 trial included 203 individuals at risk of, but without prior, cardiovascular events and LDL-C ≥2.6 mmol/L, despite maximally tolerated statins. Inclisiran 284 mg or placebo was administered on Days 1, 90, and thereafter every 6 months up to 540 days. Co-primary endpoints were percentage LDL-C change from baseline to Day 510 and time-adjusted change from baseline after Day 90 and up to Day 540. Key secondary endpoints included percentage and absolute changes in atherogenic lipoproteins. Safety was assessed over 540 days. The mean baseline (SD) LDL-C was 3.6 (1.5) mmol/L. At Day 510, the placebo-corrected LDL-C change with inclisiran was −43.7% [95% confidence interval (CI): −52.8 to −34.6] with a corresponding time-adjusted change of −41.0% (95% CI: −47.8 to −34.2); (P &lt; 0.0001). The placebo-corrected absolute change in LDL-C at Day 510 with inclisiran was −1.5 mmol/L (95% CI: −1.8 to −1.2), with a respective time-adjusted change of −1.3 mmol/L (95% CI: −1.6 to −1.1). Inclisiran significantly lowered non-HDL cholesterol and apolipoprotein B (apoB) at Day 510 vs. placebo (P &lt; 0.0001 for both), with a greater likelihood of attaining lipoprotein and apoB goals, and was well-tolerated except for mainly mild, treatment-emergent adverse events at the injection site. Conclusion Inclisiran was generally well-tolerated in primary prevention patients with elevated LDL-C, who derived significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing.
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
Gallois, Claire , Shi, Qian , Meyers, Jeffrey P., Alberts, Steven R. , Gramont, Aimery de , Sobrero, Alberto F. , Haller, Daniel G. , Oki, Eiji , Shields, Anthony F. , Goldberg, Richard M. , Lonardi, Sara , Yothers, Greg , Kelly, Caroline , Boukovinas, Ioannis , Souglakos, Ioannis , Meyerhardt, Jeffrey A. , Papamichael, Demetris , Taı̈eb, Julien , Iveson, Timothy J , Alberts, Steven R , De Gramont, Aimery , Sobrero, Alberto , Haller, Daniel , Oki, Eiji , Shields, Anthony F , Goldberg, Richard M , Lonardi, Sara , Yothers, Greg , Boukovinas, Ioannis , Sinicrope, Frank A , Yoshino, Takayuki , Meyerhardt, Jeffrey A , André, Thierry , Taieb, Julien , Shi, Qian , Iveson, Timothy , Kerr, Rachel , Labianca, Roberto , Sinicrope, Frank A. , Yoshino, Takayuki , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | November 4, 2022 | Volume: 41 | Issue: 4 | Pages: 803-815

10.1200/jco.21.02726 | PMID 36306483 Get It

PURPOSE Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis. MATERIALS AND METHODS We studied the prognostic impact of ETD and EOD in patients with stage III CC from the ACCENT/IDEA databases, where patients were planned to receive 6 months of infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine plus oxaliplatin. ETD was defined as discontinuation of treatment and EOD as discontinuation of oxaliplatin only before patients had received a maximum of 75% of planned cycles. Association between ETD/EOD and overall survival and disease-free survival (DFS) were assessed by Cox models adjusted for established prognostic factors. RESULTS Analysis of ETD and EOD included 10,447 (20.9% with ETD) and 7,243 (18.8% with EOD) patients, respectively. Compared with patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, with Eastern Cooperative Oncology Group performance status ≥ 1, and for ETD, older with a lower body mass index. In multivariable analyses, ETD was associated with a decrease in disease-free survival and overall survival (hazard ratio [HR], 1.61, P < .001 and HR, 1.73, P < .001), which was not the case for EOD (HR, 1.07, P = .3 and HR, 1.13, P = .1). However, patients who received < 50% of the planned cycles of oxaliplatin had poorer outcomes. CONCLUSION In patients treated with 6 months of oxaliplatin-based chemotherapy for stage III CC, ETD was associated with poorer oncologic outcomes. However, this was not the case for EOD. These data favor discontinuing oxaliplatin while continuing fluoropyrimidine in individuals with significant neurotoxicity having received > 50% of the planned 6-month chemotherapy.
Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage
Chaudhary, Rahul, Singh, Amteshwar , Chaudhary, Rohit , Bashline, Michael, Houghton, Damon E., Rabinstein, Alejandro, Adamski, Jill , Arndt, Richard , Ou, Narith N., Rudis, Maria I. , Brown, Caitlin S. , Wieruszewski, Erin D. , Wanek, Matthew, Brinkman, Nathan , Linderbaum, Jane A. , Sorenson, Melissa A., Atkinson, John L., Thompson, Kristine M., Aiyer, Aryan, McBane, Robert D. , Singh, Amteshwar , Chaudhary, Rahul , Bashline, Michael J. , Houghton, Damon E. , Rabinstein, Alejandro A. , Wanek, Matthew

Mayo Clinic

JAMA Network Open | November 4, 2022 | Volume: 5 | Issue: 11 | Pages: e2240145

10.1001/jamanetworkopen.2022.40145 | PMID 36331504 Get It

ImportanceDirect oral anticoagulant (DOAC)–associated intracranial hemorrhage (ICH) has high morbidity and mortality. The safety and outcome data of DOAC reversal agents in ICH are limited.ObjectiveTo evaluate the safety and outcomes of DOAC reversal agents among patients with ICH.Data SourcesPubMed, MEDLINE, The Cochrane Library, Embase, EBSCO, Web of Science, and CINAHL databases were searched from inception through April 29, 2022.Study SelectionThe eligibility criteria were (1) adult patients (age ≥18 years) with ICH receiving treatment with a DOAC, (2) reversal of DOAC, and (3) reported safety and anticoagulation reversal outcomes. All nonhuman studies and case reports, studies evaluating patients with ischemic stroke requiring anticoagulation reversal or different dosing regimens of DOAC reversal agents, and mixed study groups with DOAC and warfarin were excluded.Data Extraction and SynthesisPreferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used for abstracting data and assessing data quality and validity. Two reviewers independently selected the studies and abstracted data. Data were pooled using the random-effects model.Main Outcomes and MeasuresThe primary outcome was proportion with anticoagulation reversed. The primary safety end points were all-cause mortality and thromboembolic events after the reversal agent.ResultsA total of 36 studies met criteria for inclusion, with a total of 1832 patients (967 receiving 4-factor prothrombin complex concentrate [4F-PCC]; 525, andexanet alfa [AA]; 340, idarucizumab). The mean age was 76 (range, 68-83) years, and 57% were men. For 4F-PCC, anticoagulation reversal was 77% (95% CI, 72%-82%; I2 = 55%); all-cause mortality, 26% (95% CI, 20%-32%; I2 = 68%), and thromboembolic events, 8% (95% CI, 5%-12%; I2 = 41%). For AA, anticoagulation reversal was 75% (95% CI, 67%-81%; I2 = 48%); all-cause mortality, 24% (95% CI, 16%-34%; I2 = 73%), and thromboembolic events, 14% (95% CI, 10%-19%; I2 = 16%). Idarucizumab for reversal of dabigatran had an anticoagulation reversal rate of 82% (95% CI, 55%-95%; I2 = 41%), all-cause mortality, 11% (95% CI, 8%-15%, I2 = 0%), and thromboembolic events, 5% (95% CI, 3%-8%; I2 = 0%). A direct retrospective comparison of 4F-PCC and AA showed no differences in anticoagulation reversal, proportional mortality, or thromboembolic events.Conclusions and RelevanceIn the absence of randomized clinical comparison trials, the overall anticoagulation reversal, mortality, and thromboembolic event rates in this systematic review and meta-analysis appeared similar among available DOAC reversal agents for managing ICH. Cost, institutional formulary status, and availability may restrict reversal agent choice, particularly in small community hospitals.
Evaluating the Women's Empowerment and Leadership Initiative: Supporting mentorship, career satisfaction, and well‐being among pediatric anesthesiologists
Deutsch, Nina , Yanofsky, Samuel D., Markowitz, Scott D. , Tackett, Sean , Berenstain, Laura K. , Schwartz, Lawrence , Flick, Randall P., Heitmiller, Eugenie S., Fiadjoe, John E. , Lee, Helen H. , Honkanen, Anita , Malviya, Shobha , Lee, Jennifer K. , Schwartz, Jamie McElrath , Flick, Randall

Mayo Clinic

Pediatric Anesthesia | November 4, 2022 | Volume: 33 | Issue: 1 | Pages: 6-16

10.1111/pan.14596 | PMID 36331372 Get It

AbstractThe Society for Pediatric Anesthesia launched the Women's Empowerment and Leadership Initiative (WELI) in 2018 to empower highly productive women pediatric anesthesiologists to achieve equity, promotion, and leadership. WELI is focused on six career development domains: promotion and leadership, networking, conceptualization and completion of projects, mentoring, career satisfaction, and sense of well‐being. We sought feedback about whether WELI supported members' career development by surveys emailed in November 2020 (baseline), May 2021 (6 months), and January 2022 (14 months). Program feedback was quantitatively evaluated by the Likert scale questions and qualitatively evaluated by extracting themes from free‐text question responses. The response rates were 60.5% (92 of 152) for the baseline, 51% (82 of 161) for the 6‐month, and 52% (96 of 185) for the 14‐month surveys. Five main themes were identified from the free‐text responses in the 6‐ and 14‐month surveys. Members reported that WELI helped them create meaningful connections through networking, obtain new career opportunities, find tools and projects that supported their career advancement and promotion, build the confidence to try new things beyond their comfort zone, and achieve better work–life integration. Frustration with the inability to connect in‐person during the coronavirus‐19 pandemic was highlighted. Advisors further stated that WELI helped them improve their mentorship skills and gave them insight into early career faculty issues. Relative to the baseline survey, protégés reported greater contributions from WELI at 6 months in helping them clarify their priorities, increase their sense of achievement, and get promoted. These benefits persisted through 14 months. Advisors reported a steady increase in forming new meaningful relationships and finding new collaborators through WELI over time. All the members reported that their self‐rated mentoring abilities improved at 6 months with sustained improvement at 14 months. Thus, programs such as WELI can assist women anesthesiologists and foster gender equity in career development, promotion, and leadership.
High-resolution structural analysis of enterovirus-reactive polyclonal antibodies in complex with whole virions
Reddy, Vijay , Ward, Andrew B. , Schulze, Autumn J. , Reddy, Vijay S , Ward, Andrew B , Antanasijevic, Aleksandar

Mayo Clinic

PNAS Nexus | November 4, 2022 | Volume: 1 | Issue: 5 | Pages: No page available

10.1093/pnasnexus/pgac253 | PMID 36712368 Get It

Abstract Non-polio enteroviruses (NPEVs) cause serious illnesses in young children and neonates, including aseptic meningitis, encephalitis, and inflammatory muscle disease, among others. While over 100 serotypes have been described to date, vaccine only exists for EV-A71. Efforts toward rationally designed pan-NPEV vaccines would greatly benefit from structural biology methods for rapid and comprehensive evaluation of vaccine candidates and elicited antibody responses. Toward this goal, we introduced a cryo-electron-microscopy-based approach for structural analysis of virus- or vaccine-elicited polyclonal antibodies (pAbs) in complex with whole NPEV virions. We demonstrated the feasibility using coxsackievirus A21 and reconstructed five structurally distinct pAbs bound to the virus. The pAbs targeted two immunodominant epitopes, one overlapping with the receptor binding site. These results demonstrate that our method can be applied to map broad-spectrum polyclonal immune responses against intact virions and define potentially cross-reactive epitopes.